Natural Products Insider is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

The case for DSHEA reform

Short Legal Briefs E6
In this episode of “short legal briefs” with host Josh Long, a professor at Harvard Medical School whose research has identified drugs in “dietary supplements,” joins a former FDA official who leads an advocacy group in the nation’s capital to discuss the need for reform of the Dietary Supplement Health and Education Act of 1994 (DSHEA).

Peer-reviewed research published this month disclosed a substance prescribed in Russia as a drug was being marketed in dietary supplements in the U.S. even after FDA issued an advisory in 2019 clarifying phenibut was not a legal supplement ingredient.

Dr. Pieter Cohen, an associate professor of medicine with Harvard Medical School, highlights researchers’ findings, while the president of the Center for Science in the Public Interest (CSPI), Dr. Peter Lurie, weighs in on his advocacy group’s investigation that separately found several retailers marketing phenibut in supplements, foods or other products.

Drs. Cohen and Lurie also offer reasons for their support of reform of DSHEA, including an FDA proposal that would require dietary supplement products be listed with the agency.

Discussing the notion of DSHEA reform, Cohen concluded: “There’s a lot of opportunity to collaborate on this, and it remains an exciting time for us to come to some great solutions that can enhance the safety of supplements for all consumers.”


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.